JNCE · Jounce Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $23.75M | $26.20M | $30.11M | - | $23.29M | $22.10M | $20.51M | - | $18.00M |
| SG&A | - | $7.65M | $7.51M | $7.35M | - | $6.85M | $7.32M | $7.62M | - | $7.10M |
| Total Operating Expenses | - | $31.41M | $33.71M | $37.46M | - | $30.14M | $29.42M | $28.12M | - | $25.10M |
| D&A | - | - | - | $590.0K | - | - | - | $785.0K | - | - |
| Operating Income | - | ($31.41M) | ($33.71M) | ($37.46M) | - | ($30.14M) | ($4.05M) | ($26.58M) | - | ($25.10M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $5.0K | $12.0K | $1.0K | - | $6.0K | $2.0K | $1.0K | - | $2.0K |
| Net Income | - | ($31.00M) | ($33.51M) | ($37.37M) | - | ($30.09M) | ($4.01M) | ($26.54M) | - | ($24.90M) |
| EPS - Basic | - | ($0.60) | ($0.65) | ($0.58) | - | ($0.59) | ($0.82) | - | - | ($0.73) |
| EPS - Diluted | - | ($0.60) | ($0.65) | ($0.58) | - | ($0.59) | ($0.08) | - | - | ($0.73) |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150.57M | $77.11M | $77.74M | $60.41M | $95.53M | $145.37M | $140.81M | $196.27M | $147.49M | $67.10M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.10M | $1.11M | $3.44M | $1.90M | $1.67M | $1.75M | $2.48M | $1.63M | $2.04M | $2.71M |
| Current Assets | $197.23M | $139.93M | $157.35M | $164.84M | $190.83M | $229.25M | $257.12M | $267.01M | $211.39M | $107.46M |
| Total Assets | $212.55M | $158.08M | $188.90M | $214.67M | $252.70M | $280.38M | $306.16M | $305.15M | $244.24M | $135.83M |
| Current Liabilities | $23.57M | $21.80M | $23.20M | $16.70M | $18.90M | $18.10M | $15.84M | $12.93M | $19.32M | $16.28M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $29.44M | $28.72M | $31.17M | $25.71M | $28.89M | $29.02M | $27.70M | $25.70M | $32.94M | $30.75M |
| Stockholders' Equity | $183.11M | $129.36M | $157.73M | $188.96M | $223.81M | $251.37M | $278.46M | $279.45M | $211.29M | $105.09M |
| Retained Earnings | ($292.79M) | ($343.75M) | ($312.75M) | ($279.24M) | ($241.87M) | ($211.64M) | ($181.55M) | ($177.54M) | ($151.00M) | ($186.47M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($33.17M) | - | - | - | ($33.55M) | - | - |
| Investing Cash Flow | - | - | - | ($2.36M) | - | - | - | ($9.62M) | - | - |
| Financing Cash Flow | - | - | - | $409.0K | - | - | - | $91.95M | - | - |
| CapEx | - | - | - | $107.0K | - | - | - | $158.0K | - | - |
| Free Cash Flow | - | - | - | ($33.27M) | - | - | - | ($33.71M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.89 | - | - | - | 1.27 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -19.6% | -17.7% | -17.4% | - | -10.7% | -1.3% | -8.7% | - | -18.3% |
| Return on equity | - | -24.0% | -21.2% | -19.8% | - | -12.0% | -1.4% | -9.5% | - | -23.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.37 | 6.42 | 6.78 | 9.87 | 10.10 | 12.67 | 16.23 | 20.66 | 10.94 | 6.60 |
| Quick ratio | 8.37 | 6.42 | 6.78 | 9.87 | 10.10 | 12.67 | 16.23 | 20.66 | 10.94 | 6.60 |
| Cash ratio | 6.39 | 3.54 | 3.35 | 3.62 | 5.05 | 8.03 | 8.89 | 15.19 | 7.63 | 4.12 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.16 | 1.22 | 1.20 | 1.14 | 1.13 | 1.12 | 1.10 | 1.09 | 1.16 | 1.29 |
| Liabilities / Assets | 0.14 | 0.18 | 0.17 | 0.12 | 0.11 | 0.10 | 0.09 | 0.08 | 0.13 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -4.2% | -732.7% | -40.9% | - | -20.1% | 85.7% | 2.2% | - | - |
| Net income growth (YoY) | - | -3.0% | -735.5% | -40.8% | - | -20.8% | 85.7% | -0.3% | - | - |
| EPS growth (YoY) | - | -1.7% | -712.5% | - | - | 19.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 1.3% | - | - | - | -42.9% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -18.2% | -48.5% | -43.4% | -32.4% | 5.9% | 139.2% | 118.8% | 83.2% | 21.0% | -45.1% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Jounce Therapeutics against the 5 most active filers in the same SIC group.